StockData
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc (XFOR) stock

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$3.09+0.26 (+9.19%)

Close on Nov 17, 2026Market cap $306.36MP/E –Yield –

X4 Pharmaceuticals price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

X4 Pharmaceuticals's price to book ratio was 2.0× on Nov 11, 2026, against 1.5× a year earlier. Over the last 5 years it ranged from 0.4× to 163.7×, with a median of 1.9×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.0×+0.4
2025Dec 31, 20251.6×−0.4
2024Dec 31, 20242.1×+0.0
2023Dec 29, 20232.0×+0.9
2022Dec 30, 20221.1×+0.3
2021Dec 31, 20210.8×−0.3
2020Dec 31, 20201.2×−0.5
2019Dec 31, 20191.7×–

More X4 Pharmaceuticals figures

See a number that looks wrong?